NCT03844061: Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- State
- Under way
- Phase
- Phase 2
- People
- 30 planned
- Started
- 29 Jul 2019
- Primary completion
- 30 Aug 2027
- Arms
- MMF + Rituximab + Belimumab
- Results
- None posted
- 18 Feb 2019: Trial registered
- 29 Jul 2019: Trial started